A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Sponsor: Janssen Research & Development, LLC
This PHASE4 trial investigates Arthritis, Psoriatic and is currently ongoing. Janssen Research & Development, LLC leads this study, which shows 47 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
47 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE4
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE4
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE4
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE4
▶ Show 42 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE4
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE4
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE4
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE4
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE4
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE4
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE4
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE4
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE4
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE4
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE4
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE4
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE4
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE4
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE4
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE4
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE4
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE4
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE4
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE4
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE4
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE4
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE4
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE4
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE4
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE4
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE4
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE4
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE4
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE4
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE4
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE4
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE4
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE4
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE4
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .